Regulatory affairs-Introduction to CTD

05/02/23 1

Drug Regulatory Affairs

By, Mahesh Shinde

The Bridge BetweenPharma Companies &

Govt. Agency

2

Regulatory affairs

• It is by no means boring! It’s interesting.

3

Role of Regulatory Affairs

What is this?

4

Regulatory System

YES YES YES

YES

YES

YES

Govt. Prescriber Distributor Patient

Govt.

Prescriber

Distributor

Patient

5

• Drug = medicinal product = pharmaceutical product

6

Drug regulatory affairsAny activity with drugs

By whom? (the authority)

no (=does not belong to drug regulatory affairs)

yes

Prior authorisation needed?

Based on which (objective and subjective) criteria?

Subject to regular control (quality, inspection)?

By whom? (the authority)Based on which (objective and subjective) criteria?

7

Activities with drugs…

• research (chemical, biological)• clinical trials on human beings• manufacture• registration

– evaluation– authorisation

• (wholesale) distribution

continued

8

Activities with drugs (cont’d)

• pricing• prescribing• reimbursement/subsidy• advertising (if any)• special control (e.g. narcotics)• post-marketing surveillance

– national drug quality control lab– adverse effect reporting system

• (retail) distribution• etc.

poppy

Quality = Quality of Personnel (Qualification, Training…) + Quality of Materials (Specifications, Approved

Suppliers...) + Quality of Means (Qualified equipment's,

maintenance…) + Quality of Media (GMP premises, Controlled

environment…)

+ Quality of Methods (Calibration, Validation…)

Composition of Quality

9

QUALITYQUALITYRaw Materials

Personnel

Procedures

Validated processes

EquipmentPremises

Environment

Packing Materials

Functions of a Quality Unit

10

Quality Control– Sampling and testing of components

Raw materials, Packing materials, intermediates and finished products

– Compliance to Good Laboratory Practices (GLPs)

Functions of a Quality Unit

11

Quality Assurance– Designing robust quality

systems

– Ensure compliance to relevant regulatory requirements

– Ensure compliance to requirements of Good Manufacturing Practices (GMP)

Value addition in QA Value addition in QA functionfunction

12

Quality Assurance:– Perform structured self-

inspection audits at regular intervals to prevent any failure or non-conformance

– Critically analyze the quality non-conformance issues and suggest corrective and preventive actions

Value addition in QA function

13

Quality Assurance:– Perform documentation

audit to ensure realistic recording of all the relevant process parameters

– Review the adequacy of in-process control checks to prevent any potential failures

Value addition in QA function

14

Quality Assurance:– Training & Knowledge

Management

– Perform literature survey of FDA / ICH / ISO guidelines, revisions in the Pharmacopoeial specifications and the current regulatory requirements and provide training to the production personnel.

What is Dossier?

15

• Dossier is collection or file of documents that contains all the technical data of pharmaceutical product to be approved/ registered /marketed in country.

• It is commonly called as registration dossier.

In US : New Drug ApplicationIn EU : Marketing Authorization Application

What is DMF?Drug Master File (DMF)

• US : United State Drug Master File (US-DMF)• EU : European Drug Master File (EDMF) or Active Substance Master File (ASMF)

• TYPES OF DMFs• The types of DMFs are:• Type I - Manufacturing Site, Facilities, Operating Procedures, and Personnel

(no longer applicable)• Type II - Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product• Type III - Packaging Material• Type IV - Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation• Type V - FDA Accepted Reference Information

16

What is CTD/eCTD?Common Technical Documents (CTD)

• The Common Technical Document (CTD) is a set of specification for application dossier for the registration of Medicines and designed to be used across Europe, United States & ROW.

• Its electronic version called as Electronic Common Technical Document (eCTD)

17

The CTD Triangle

18

Module 1 Administrative & Prescribing Information (Region Specific):

Should Contain Documents specific to each region:

19

Module 1 Administrative & Prescribing Information (Region Specific):

(1) SITE MASTER PLAN OF PLANT(2) COMPANY PROFILE IN SHORT(3) ATTESTED COPY OF MANUFACTURING LICENCE(4) ATTESTED COPY OF PRODUCT PERMISSION FROM FDA(5) ATTESTED COPY OF COPP(6) ATTESTED COPY OF WHO/GMP CERTIFICATE(7) COA OF SAMPLE(8) ATTESTED COPY OF WHOLE SELL LICENCE.(9) LETTER OF AUTHORISATION

20

Module 2 CTD Summaries (QOS):

21

It contain 7 sections in the following order: 2.1 CTD Table of content (Module 2-5)2.2 CTD Introduction2.3 Quality Overall Summary

2.4 Non-Clinical Overview

2.5 Clinical Overview

2.6 Non-Clinical Summary

2.7 Clinical Summary

Module 3 Quality: Chemistry, Manufacturing & Controls (CMC)

22

3.1 Table of content (Module 3)3.2 Body of Data

3.2 S Drug Substance 3.2 S1 General Information (Name, Mfg.) 3.2 S2 Manufacture

3.2 S3 Characterization 3.2 S4 Control of Drug Substance (Specification, Analytical procedures, Validation of Analytical procedures, etc. )

3.2 S5 Reference Standards

3.2 S6 Stability


23

3.2 P Drug Product 3.2 P1 Description and Composition of the Drug Product3.2 P2 Pharmaceutical Development (name, dosage form)3.2 P3 Manufacturer

3.2 P4 Control of Excipients

3.2 P5 Control of Drug Product (Specification, Analytical procedures, Validation of Analytical procedures, etc. )

3.2 P6 Reference Standards

3.2 P7 Stability


24

3.2 A Appendices3.2 A1 Facility & Equipment's

3.2 A2 Advertising agents safety evaluation

3.2 A3 Excipients

3.2 R Regional Information

3.3 Literature References

Module 4 Non-Clinical Study Reports:

25

4.1 Table of content (Module 4)4.2 Study Reports

4.2.1 Pharmacology4.2.1. 1. Pharmacodynamics 4.2.1. 2. Safety Pharmacology 4.2.1. 3. Pharmacodynamics Drug Interaction

4.2.2 Pharmacokinetics4.2.2. 1. ADME 4.2.2. 2. Pharmacokinetic Drug Interaction 4.2.2. 3. Other Pharmacokinetic Study

Module 4 Non-Clinical Study Reports:

26

4.2.3 Toxicology4.2.3. 1. Single/Repeat Dose Toxicity 4.2.3. 2. Genotoxicity

4.2.3. 3. In-Vivo/Vitro Toxicity

4.2.3. 4. Carcinogenicity 4.2.3. 5. Local Tolerance/Dependence 4.2.3. 6. Other Studies


Module 5 Clinical Study Reports:

27

5.1 Table of content (Module 5)5.2 Tabular listing of Clinical Studies 5.3 Clinical study reports

5.3.1 Reports of Biopharmaceutical (BA-BE) Study 5.3.2 Reports of Pharmacokinetic (biomaterial) study 5.3.3 Reports of Pharmacokinetic (PK) studies 5.3.4 Reports of Pharmacodynamics (PD) studies 5.3.4 Reports of Efficacy and Safety studies 5.3.4 Reports of Post-Marketing experience 5.3.4 Case Report Forms & Individual patient listings


Sample

• Dossier • DMF

Regulatory Compliance

National Regional Global

Regulatory Compliance

29

National (India)

License Application Receipt

Manufacturing license Form No. 24 Form No. 25

Test license Form No. 30 Form No. 29

Import license Form No. 12 Form No.11

30

Compliance to (Drugs & Cosmetics Act 1940 & Rules under)

National (India)

Drug Regulatory approval

Schedule Y ComplianceForm 44

Manufacturing Schedule M Compliance

Documentation Schedule U Compliance

Packaging Schedule P Compliance

API/Excipients/FP/PM IP Inputs if not BP/USP/ or IH

31

Regulatory Dossier Regulatory approach:

Parameters US Europe Other markets India

API USP Ph.Eur. USP / Ph.Eur. IP

USDMF COS (CEP) / EDMF DMF requirement depends on the target market

Excipients USP Ph.Eur. USP / Ph.Eur. IP

Reference product US Europe Depends on the target market

Indian (if not available, then US or Europe)

Packaging materials

Complying to USP Ph.Eur. USP / Ph.Eur. IP

Finished product USP As per Ph.Eur. General requirement

USP / Ph.Eur. IP

Submission batch 1 2 2 or 3 -

Submission batch size

100,000 units or 1/10th of commercial

batch

100,000 units or 1/10th of

commercial batch

Depends on the target market

No such requirement

32

Regulatory Dossier Regulatory approach:

Parameters US Europe Other markets India

Stability data 1 batch 2 batches 2 or 3 batches 3 batches

Stability condition Zone I & II condition Zone I & II condition Depends on the target market

Zone IV condition

Comparative dissolution study

3 media 3 media Depends on the target market

1 to 3 media

Input materials TSE/BSE, OVI statements

TSE/BSE Depends on the target market

No such requirement

Packaging materials Food grade certificate Food grade certificate Depends on the target market

No such requirement

Method validation data As per ICH ICH ICH No such guideline

Process validation data

Not required Not required Depends on the target market

Not required for submission

Bioequivalence study US reference product under fast and fed

condition

European reference product (generally

under fasting condition)

Generally fasting bio study

Fasting bio study

Bioequivalence study In USFDA approved CRO anywhere in the

world

MHRA/EU approved CRO anywhere

Depends on the target market

Indian study required

33

Regulatory Authorities India: DCGI & State Drug Administration European Union: MHRA USA : Food and Drug Administration (FDA) Australia : Therapeutic Goods Administration Newzeland : Medsafe South Africa: Medicines council control Japan : Ministry of Health & Labour Welfare Switzerland : Swissmedic Brazil : ANVISA (The National Health Surveillance Agency) Mexico: COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) Chile : ISP - Instituto de Salud Pública de Chile Columbia: INVIMA – Instituto Nacional de Vigilancia de Medicamentos Alimentos Carrera 68 D No. 17 - 11 / 21 Argentina: ANMAT - set in 1992 Argentine National Administration of Drugs, Food & Medical TechnologyFrance: Agence Française de Sécurité Sanitaire des Produits de SantéGermany: Federal Institute for Drugs and Medical Devices

34

Important sitesRegulatory sites:

www.fda.govwww.tga.gov.au http://www.emea.europa.eu/ www.ministeriodesalud.go.cr www.mspas.gob.gthttp://www.minsa.gob.pa/minsa2006/inicio.phphttp://www.minsa.gob.nihttp://www.salud.gob.hn/www.cssp.gob.svhttp://www.sns.gov.bo/http://www.inh.gov.ec/http://www.mspbs.gov.py/http://www.msp.gub.uy/index_1.htmlhttp://digemid.minsa.gob.pehttp://www.inhrr.gov.vehttp://pharmacos.eudra.org

35

Important sitesUseful links:

•www.usp.org •www.pheur.org •www.jpdb.nihs.go.jp •www.picscheme.org •www.pda.org •www.phrma.org •www.pharmacy.org •www.elsevier.com •www.ich.org•www.ijpsonline.com •www.pharmj.com •www.scripnews.com

36

E-mail: [email protected]

37

Regulatory affairs-Introduction to CTD

Healthcare

Transcript of Regulatory affairs-Introduction to CTD